Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Cardiology
•
Cardio-Rheumatology
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Related Questions
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
What would be the minimum duration of IL-1 therapy you would recommend for chronic pericarditis?
How do you approach management of recurrent idiopathic pleuropericarditis?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
How do you approach the management of a patient with RA on methotrexate who has gingivitis or or frequent cavities?
How would you manage a patient with RA on abatacept now experiencing recurrent pericarditis not responsive to colchicine?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Would you stop methotrexate or leflunomide if MCV increases after starting the medication with no other parameters of anemia or leukopenia?
Can serological markers such as KL-6, MMP-7, and anti-CarP be used to monitor interstitial lung disease in patients with rheumatoid arthritis in clinical practice?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
